Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 82
Filter
1.
Rev. bras. oftalmol ; 81: e0035, 2022. tab
Article in English | LILACS | ID: biblio-1376791

ABSTRACT

ABSTRACT Objective: To evaluate the efficacy of mitomycin C in anatomical and functional success after modified transcanalicular diode laser dacryocystorhinostomy. Methods: A prospective, double-blinded, randomized placebo-controlled study compared the effect of topical mitomycin C on modified transcanalicular diode laser dacryocystorhinostomy. Group 1 had modified transcanalicular diode laser dacryocystorhinostomy with topical saline, while Group 2 had modified transcanalicular diode laser dacryocystorhinostomy with topical mitomycin C. Success was defined as anatomical patency and relief of symptoms at the end of 6 months. Results: Six months after surgery, Group 1 (30 patients) showed anatomical and functional success rates of 86.7% and 83.3%, respectively. Group 2 (32 patients) showed anatomical and functional success rates of 87.5% and 84.3%, respectively. There was no statistically significant difference between the groups 1 and 2 (p = 1.000). Conclusion: The use of mitomycin C did not improve the anatomical and functional success rates of modified transcanalicular diode laser dacryocystorhinostomy compared to placebo.


RESUMO Objetivo: Avaliar a eficácia da mitomicina C no sucesso anatômico e funcional após dacriocistorrinostomia transcanalicular com laser de diodo. Métodos: Estudo prospectivo, duplo-cego, randomizado e controlado por placebo. Comparou o efeito da mitomicina C tópica na dacriocistorrinostomia transcanalicular com laser de diodo. No Grupo 1, foi utilizada apenas solução salina tópica, enquanto no Grupo 2 foi utilizada mitomicina C tópica. O sucesso foi definido como permeabilidade da via lacrimal e alívio dos sintomas ao final de 6 meses. Resultados: Seis meses após a cirurgia, o Grupo 1 (30 pacientes) apresentou taxas de sucesso anatômico e funcional de 86,7% e 83,3%, respectivamente. O Grupo 2 (32 pacientes) apresentou taxas de sucesso anatômico e funcional de 87,5% e 84,3%, respectivamente. Não houve diferença estatística significante entre os Grupos 1 e 2 (p=1,000). Conclusão: O uso de mitomicina C não melhora as taxas de sucesso anatômico e funcional do dacriocistorrinostomia transcanalicular com laser de diodo em comparação ao placebo.


Subject(s)
Humans , Male , Female , Middle Aged , Dacryocystorhinostomy/methods , Mitomycin/administration & dosage , Mitomycin/therapeutic use , Mitomycin/pharmacology , Lasers, Semiconductor/therapeutic use , Nasolacrimal Duct/drug effects , Placebos , Random Allocation , Double-Blind Method , Prospective Studies , Follow-Up Studies , Treatment Outcome , Chemotherapy, Adjuvant , Dacryocystitis/surgery , Laser Therapy/methods , Lacrimal Duct Obstruction/therapy , Nasolacrimal Duct/surgery
2.
Rev. cuba. oftalmol ; 34(3): e1071, 2021. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1352029

ABSTRACT

Objetivo: Evaluar la utilidad de dos concentraciones de mitomicina C para la prevención del haze en la queratectomía fotorrefractiva. Métodos: Se realizó un estudio experimental aleatorizado en 26 ojos de 17 pacientes con defectos miópicos. Los pacientes fueron asignados a dos grupos según las dosis de mitomicina C (0,02 por ciento grupo 1 y 0,002 por ciento grupo 2). La variable de respuesta principal fue la presencia de haze. Se buscó correlación entre la magnitud del haze con grado de ametropía tratada, profundidad de ablación, microscopia endotelial y resultados visuales y refractivos. Resultados: A los 6 meses la mayoría de los pacientes del grupo 1 no presentó haze (ocho ojos / 57 por ciento), y del grupo 2 mantuvieron haze 0,5 (6 ojos / 50 por ciento). En la ametropía severa el haze en el grupo 2 fue mayor que en el grupo 1 durante todo el posoperatorio, y se observó la mayor diferencia al sexto mes con 0,5 ± 0,4 vs. 1,5 ± 0,32. En ablaciones > 75 micras el grupo dos terminó con más haze que el uno, con 0,5 ± 0,44 vs. 1,75 ± 0,76. La agudeza visual sin corrección se vio más afectada en el grupo 2. No hubo daño endotelial en ningún grupo. Conclusión: La presencia de haze predomina en los casos tratados con dosis 0,002 por ciento de mitomicina C, comparada con la dosis 0,02 por ciento, aunque en este caso ambos grupos mantuvieron un resultado visual y refractivo adecuado y baja toxicidad endotelial.


Objective: Evaluate the usefulness of two concentrations of mitomycin C for haze prevention in photorefractive keratectomy. Methods: An experimental randomized study was conducted of 26 eyes of 17 patients with myopic defects. The patients were divided into two groups according to their mitomycin C doses (Group 1: 0.02 percent and Group 2: 0.002 percent). The main response variable was the presence of haze. Verification was performed of the correlation between haze magnitude and the degree of the ametropia treated, ablation depth, endothelial microscopy, and visual and refractive results. Results: At six months most patients in Group 1 did not have any haze (eight eyes / 57 percent), whereas 0.5 (6 eyes / 50 percent) in Group 2 still had haze. In severe ametropia, haze was larger in Group 2 than in Group 1 throughout the postoperative period, the greatest difference being observed in the sixth month with 0.5 ± 0.4 vs 1.5 ± 0.32. In ablations > 75 microns, Group 2 ended with more haze than Group 1, with 0.5 ± 0.44 vs 1.75 ± 0.76. Uncorrected visual acuity was more affected in Group 2. No endothelial damage occurred in either group. Conclusion: The presence of haze prevails in cases treated with 0.002 percent doses of mitomycin C, as compared with 0.02 percent doses, though in this case both groups maintained an appropriate visual and refractive result and low endothelial toxicity(AU)


Subject(s)
Humans , Refractive Errors/etiology , Mitomycin/therapeutic use , Photorefractive Keratectomy/methods
3.
Arq. gastroenterol ; 58(2): 253-261, Apr.-June 2021. tab, graf
Article in English | LILACS | ID: biblio-1285318

ABSTRACT

ABSTRACT BACKGROUND: Caustic ingestion and development of esophageal strictures are recognized major public health problems in childhood. Different therapeutic methods have been proposed in the management of such strictures. OBJECTIVE: To evaluate efficacy and risk of endoscopic topical application of mitomycin C in the treatment of caustic esophageal strictures. METHODS: We searched MEDLINE, EMBASE, Central Cochrane, and LILACS databases. The outcomes evaluated were dysphagia resolution rate, number of dilations performed in resolved cases, and the number of dilations performed in all patients. RESULTS: Three randomized clinical trials were included for final analysis with a total of 190 patients. Topical mitomycin C application group showed a significant increase in dysphagia resolution rate, corresponding to a 42% higher dysphagia resolution as compared to endoscopic dilation alone, with statistical significance between the two groups (RD: 0.42 - [CI: 0.29-0.56]; P-value <0.00001). The mean number of dilations performed in resolved cases were significantly less in the topical mitomycin C application group, compared to endoscopic dilations alone, with statistical significance between the two groups (MD: 2.84 [CI: 1.98-3.69]; P-value <0.00001). When comparing the number of dilations in all patients, there was no statistical difference between the two groups (MD: 1.46 [CI: -1.53-4.44]; P-value =0.34). CONCLUSION: Application of topical mitomycin C with endoscopic dilations in caustic esophageal strictures was more effective in dysphagia resolution than endoscopic therapy alone in the pediatric population. Moreover, topical mitomycin C application also reduced the number of dilation sessions needed to alleviate dysphagia without rising morbidity.


RESUMO CONTEXTO: A ingestão de soda cáustica e o desenvolvimento de estenoses esofágicas são reconhecidos como importantes problemas de saúde pública na infância. Diferentes métodos terapêuticos têm sido propostos no manejo dessas estenoses. OBJETIVO: Avaliar a eficácia e o risco da aplicação endoscópica tópica de mitomicina C no tratamento de estenoses esofágicas cáusticas. MÉTODOS: Buscamos as bases de dados MEDLINE, EMBASE, Central Cochrane e LILACS. Os desfechos avaliados foram taxa de resolução da disfagia, número de dilatações realizadas nos casos resolvidos e número de dilatações realizadas em todos os pacientes. RESULTADOS: Três ensaios clínicos randomizados foram incluídos para análise final com um total de 190 pacientes. O grupo de aplicação de mitomicina C tópica apresentou aumento significativo na taxa de resolução da disfagia, correspondendo a uma resolução da disfagia 42% maior em comparação à dilatação endoscópica isolada, com significância estatística entre os dois grupos (RD: 0,42 - [IC: 0,29-0,56]; P-valor <0,00001). O número médio de dilatações realizadas em casos resolvidos foi significativamente menor no grupo de aplicação tópica de mitomicina C, em comparação com as dilatações endoscópicas isoladas, com significância estatística entre os dois grupos (MD: 2,84 [IC: 1,98-3,69]; P-valor <0,00001). Ao comparar o número de dilatações em todos os pacientes, não houve diferença estatística entre os dois grupos (MD: 1,46 [IC: -1,53-4,44]; valor de P=0,34). CONCLUSÃO: A aplicação de mitomicina C tópica com dilatações endoscópicas em estenoses esofágicas cáusticas foi mais eficaz na resolução da disfagia do que a terapia endoscópica isolada na população pediátrica. Além disso, a aplicação tópica de mitomicina C também reduziu o número de sessões de dilatação necessárias para aliviar a disfagia sem aumentar a morbidade.


Subject(s)
Humans , Child , Caustics/toxicity , Esophageal Stenosis/chemically induced , Esophageal Stenosis/drug therapy , Randomized Controlled Trials as Topic , Administration, Topical , Esophagoscopy , Treatment Outcome , Mitomycin/therapeutic use
4.
Rev. cuba. oftalmol ; 34(1): e942, 2021. graf
Article in Spanish | LILACS, CUMED | ID: biblio-1289538

ABSTRACT

La oftalmomiasis es una enfermedad poco frecuente, causada por artrópodos; en este caso por la mosca adulta. Presentamos el caso de una paciente femenina, de 44 años de edad, con antecedentes de inmunosupresión severa secundaria a VIH, quien fue atendida en el Servicio de Oftalmología por molestia ocular. Presentaba un aumento de volumen circunscrito en conjuntiva que se extendía sobre la córnea nasal del ojo izquierdo, de aspecto blanco nacarado, deslustrado. Se le realizó exéresis de la lesión y crioterapia. Posteriormente se le aplicó colirio de mitomicina C. A los siete meses la paciente regresó a la consulta con un cuadro de complicación franca y severa de la lesión, con destrucción de los tejidos de la órbita y múltiples cavernas ocupadas por cientos de larvas de moscas(AU)


Ophthalmomiasis is a rare disease, caused by arthropods; in this case by the adult fly. We present the case of a 44-year-old female patient, with a history of severe immunosuppression secondary to HIV, who was treated at the Ophthalmology Service for ocular discomfort. She presented a circumscribed increase in volume in the conjunctiva that extended over the nasal cornea of ​​the left eye, with a pearly white, tarnished appearance. Excision of the lesion and cryotherapy were performed. Subsequently, mitomycin C eye drops were applied. Seven months later, the patient returned to the consultation with a frank and severe complication of the lesion, with destruction of the tissues of the orbit and multiple caverns occupied by hundreds of fly larvae(AU)


Subject(s)
Humans , Female , Adult , Mitomycin/therapeutic use , Cryotherapy/methods , Rare Diseases/therapy , Myiasis/epidemiology
5.
Rev. bras. oftalmol ; 80(4): e0018, 2021. tab, graf
Article in English | LILACS | ID: biblio-1288632

ABSTRACT

ABSTRACT Objective: To describe ocular surface findings in impression cytology obtained from healthy rabbit conjunctiva treated with interferon alpha-2b eyedrop, and compare them to findings after use of mitomycin C 0.02%. Methods: An experimental study using a rabbit model was performed between September 2013 and October 2014 at the Faculdade de Medicina de Marília, Universidade Federal de São Paulo, Clínica de Olhos Moacir Cunha. Thirty New Zealand white rabbits were divided into 6 groups and received interferon alpha-2b or mitomycin C 0.02%. Impression cytology (IC) was performed prior to topical applications and at15, 30 and 60 days of use. The following variables were analyzed in impression cytology: goblet cells, cellularity, cell-to-cell adhesion, nucleus/cytoplasm ratio, nuclear chromatin, inflammatory cells keratinization, and cytomegaly. Results: The major findings in impression cytology after us of interferon alpha-2b included loss of goblet cells (50.8%), reduced cell-to-cell adhesion (26.2%), abnormal nucleus/cytoplasm ratio (20%) and reduced cellularity (15.4%). After use of mitomycin C 0.02%, the most common changes included loss of goblet cells (46.2%), abnormal nucleus/cytoplasm ratio (25.6%), less cell-to-cell adhesion (23.1%), and reduced cellularity (20.5%). There were no significant differences in any variable when comparing impression cytology after interferon alpha-2b and after mitomycin C 0.02%. Goblet cell loss was more pronounced at days 30 and 60, as compared to impression cytology at day 15 for both drugs. Conclusion: The loss of goblet cells, reduced cell-to-cell adhesion and cellularity, along with abnormal nucleus/cytoplasm ratio were the most common findings in impression cytology after use of interferon alpha-2b. These findings are similar to those described for use of mitomycin C 0.02%. ..


RESUMO Objetivo: Descrever os achados em citologia de impressão de conjuntiva sadia de coelho submetida ao uso de colírio de interferon alfa-2b e compará-los ao que foi encontrado após uso da mitomicina C 0,02%. Métodos: Estudo experimental realizado em modelo animal no período entre setembro de 2013 e outubro de 2014 nas dependências da Faculdade de Medicina de Marília, da Universidade Federal de São Paulo e da Clínica de Olhos Moacir Cunha. Trinta coelhos albinos da raça Nova Zelândia foram divididos em seis grupos e receberam interferon alfa-2b ou mitomicina C. A citologia de impressão foi realizada antes do início dos colírios e após 15, 30, 60 dias de seu uso. As seguintes variáveis foram analisadas na citologia de impressão: células caliciformes, celularidade, adesão intercelular, razão núcleo/citoplasma, cromatina, células inflamatórias, queratinização e citomegalia. Resultados: Os principais achados na citologia de impressão após o uso do interferon alfa-2b foram a redução de células caliciformes (50,8%), a diminuição da adesão intercelular (26,2%), a alteração da razão N/C (20%) e a redução da celularidade (15,4%). Após o uso da mitomicina C 0,02%, foram mais frequentes a redução das células caliciformes (46,2%), a alteração da razão N/C (25,6%), a adesão intercelular (23,1%) e a redução da celularidade (20,5%). Não houve diferença estatisticamente significante para nenhuma das variáveis estudas quando se compararam as citologias de impressão após interferon alfa-2b com as citologias de impressão após mitomicina C 0,02%. Independentemente da substância utilizada, as citologias colhidas 30 e 60 dias após início das drogas apresentaram maior redução de células caliciformes quando comparadas com as citologias de impressão colhidas após 15 dias. Conclusão: A redução das células caliciformes, a diminuição da adesão intercelular, a alteração da razão N/C e a diminuição da celularidade foram as alterações mais frequentes na citologia de impressão colhida após o uso de interferon alfa-2b. Os achados em citologias de impressão após o uso de interferon alfa-2b são semelhantes àqueles encontrados após o uso da mitomicina C 0,02%.


Subject(s)
Animals , Rabbits , Mitomycin/pharmacology , Conjunctiva/cytology , Cornea/cytology , Interferon alpha-2/pharmacology , Carcinoma, Squamous Cell/drug therapy , Cellulose , Cytological Techniques , Mitomycin/therapeutic use , Conjunctiva/drug effects , Conjunctiva/ultrastructure , Conjunctival Neoplasms/drug therapy , Cell Culture Techniques , Cornea/drug effects , Cornea/ultrastructure , Cytodiagnosis/methods , Interferon alpha-2/therapeutic use , Micropore Filters
6.
Rev. cuba. oftalmol ; 33(4): e914, oct.-dic. 2020. graf
Article in Spanish | LILACS, CUMED | ID: biblio-1156584

ABSTRACT

El tratamiento del glaucoma se realiza con el objetivo de disminuir los niveles de presión intraocular, único factor tratable hasta el momento, y debe ser individualizado. Se presenta un paciente masculino de 54 años de edad, de piel mestiza, intelectual, con antecedentes de aparente salud y diagnóstico de glaucoma desde hace 10 años. Se realizó trabeculectomía con antimetabolito (mitomicina C) en el ojo izquierdo en el año 2012 por daño glaucomatoso avanzado. En el año 2016 acudió a nuestra consulta y refirió mala visión y descontrol de la presión intraocular de ambos ojos. Se constataron cifras muy elevadas de presión intraocular en ambos ojos, superiores a 30 mmHg; en el ojo derecho la unidad de visión con su mejor corrección y un daño campimétrico muy avanzado limitado a una isla de visión central con caída hasta los 5° centrales, y el ojo izquierdo no alcanzaba la percepción luminosa. Después de combinar 3 líneas farmacológicas con la dosis máxima, los valores de la presión intraocular no eran protectores. Surgió la disyuntiva entre realizar una cirugía filtrante, temiendo al riesgo quirúrgico elevado y tratándose de un ojo único, o no practicar cirugía alguna y solo continuar con el tratamiento farmacológico a pesar de no conseguirse valores de presión intraocular meta. Se decidió realizar esclerectomía profunda no penetrante con antimetabolito (mitomicina C al 0,02 por ciento). No se presentaron complicaciones asociadas y se consiguió el descenso de la presión intraocular a 24 mmHg, por lo que al mes de la cirugía se realizó goniopuntura. Se obtuvo la presión intraocular objetivo, sin progresión del daño glaucomatoso y hubo conservación de la agudeza visual(AU)


Treatment for glaucoma is aimed at reducing the levels of intraocular pressure. This is the only factor that may be treated so far, and it should be individualized. A case is presented of a male 54-year-old mulatto patient, intellectual, with a history of apparently good health who was diagnosed with glaucoma ten years ago. Trabeculectomy with antimetabolite (mitomycin C) was performed on the patient's left eye in the year 2012 due to advanced glaucomatous damage. In the year 2016 the patient attended our service and reported poor vision and uncontrolled intraocular pressure in both eyes. Very high intraocular pressure values above 30 mmHg were confirmed in both eyes. In the right eye the vision unit with its best correction, and very advanced campimetric damage limited to a central vision island with a fall to 5° central, whereas the left eye did not achieve light perception. After combining 3 drug lines at their maximum dosage, intraocular pressure values were not protective. The dilemma arose whether to perform filtration surgery, fearing the high surgical risk, being as it was a single eye, or not to perform any surgery and just go on with the drug treatment despite not having achieved target intraocular pressure values. It was decided to perform non-penetrating deep sclerectomy with antimetabolite (0.02 percent mitomycin C). No associated complications occurred and intraocular pressured fell to 24 mmHg. Therefore, goniopuncture was performed one month after surgery. The target intraocular pressure was obtained without glaucomatous damage progression and visual acuity was preserved(AU)


Subject(s)
Humans , Male , Middle Aged , Trabeculectomy/methods , Mitomycin/therapeutic use , Intraocular Pressure/drug effects , Glaucoma/diagnosis , Glaucoma/therapy
7.
Rev. cuba. oftalmol ; 33(4): e988, oct.-dic. 2020. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1156571

ABSTRACT

Objetivo: Describir los resultados visuales e hipotensores de la trabeculotomía gonioasistida modificada y determinar sus complicaciones. Métodos: Se realizó un estudio analítico de 30 ojos; 15 de ellos (15 pacientes) recibieron trabeculotomía gonioasistida modificada (grupo caso) y 15 ojos (15 pacientes) recibieron trabeculectomía con mitomicina C (control histórico). Resultados: Predominaron los pacientes masculinos. La edad promedio del grupo con trabeculectomía fue 64,2 ± 7,3 años; mientras la del grupo con trabeculotomía gonioasistida modificada fue 69,9 ± 4,8 años. La agudeza visual mejor corregida media preoperatoria fue menor en el grupo con trabeculectomía (95 VAR/100-80 vs. 97 VAR/100-90) y la presión intraocular media fue 26,0 mmHg/24,5-30,0) y 25,0 mmHg/22,5-27,0 respectivamente. Todos los pacientes con trabeculectomía recibieron 3 colirios hipotensores en el preoperatorio, mientras el 53,3 por ciento de los tratados con trabeculotomía gonioasistida modificada requirieron 3 colirios hipotensores. Al año, la agudeza visual mejor corregida media disminuyó en el grupo con trabeculectomía (90VAR/100-75), y se mantuvo en el grupo con trabeculotomía gonioasistida modificada (97VAR/100-90). En ambos grupos se produjo una caída significativa de la PIO promedio y más del 85 por ciento de los casos requirió uno o ningún colirio para su control. Conclusiones: El resultado visual, el poder hipotensor y las complicaciones quirúrgicas al año muestran la trabeculotomía gonioasistida modificada como una técnica útil y segura. Se requieren estudios a largo plazo para evaluar su efectividad futura(AU)


Objective: Describe results one year after modified gonioscopy-assisted trabeculotomy. Methods: An analytical study was conducted of 30 eyes, 15 of which (15 patients) underwent modified gonioscopy-assisted trabeculotomy (GATTm) (case group), and 15 trabeculotomy with mitomycin C (TBT) (historical control). Results: Male patients prevailed. Mean age was 64.2 ± 7.3 years for the TBT group and 69.9 ± 4.8 years for the GATTm group. In the TBT group mean preoperative best corrected visual acuity was lower (95 VAR/100-80 vs. 97VAR/100-90), whereas mean intraocular pressure was 26.0 mmHg/24.5-30.0 and 25.0 mmHg/22.5-27.0, respectively. All TBT patients received 3 hypotensive collyriums preoperative, while 53.3 percent of the GATTm patients required 3 hypotensive collyriums. At one year, mean best corrected visual acuity was lower in the TBT group (90VAR/100-75) and remained the same in the GATTm group (97VAR/100-90). A significant mean intraocular pressure reduction was observed in both groups and more than 85 percent of the cases required either one or no collyrium for their control. Conclusions: Visual result, hypotensive effect and surgical complications at one year are evidence that modified gonioscopy-assisted trabeculotomy is a safe, useful technique. Long-term studies are required to evaluate its future effectiveness(AU)


Subject(s)
Humans , Male , Middle Aged , Glaucoma/diagnosis , Mitomycin/therapeutic use , Intraocular Pressure , Trabeculectomy/methods
8.
Int. arch. otorhinolaryngol. (Impr.) ; 24(1): 112-124, Jan.-Mar. 2020. tab, graf
Article in English | LILACS | ID: biblio-1090547

ABSTRACT

Abstract Introduction Mitomycin C is a natural antibiotic that has been used to inhibit the proliferation of fibroblasts in scar tissue. Objective To evaluate the effectiveness and safety of topical Mitomycin C as an adjuvant in the endoscopic treatment of laryngotracheal stenoses. Data synthesis A systematic review of experimental or observational studies that have evaluated the treatment of laryngotracheal stenoses with the use of topical Mitomycin C was performed. Databases researched: LILACS, PubMed, Embase, Cochrane and Web of Science. Outcomes: resolution (symptom-free time ≥ one year), number of procedures required, and complications resulting from the procedure. A total of 15 studies (involving 387 patients) were selected. Mitomycin C was administered to every patient in 11 studies, and in 4 other studies, the patients were separated into 2 groups, 1 receiving mitomycin C, and the other not. The resolution of the stenosis evaluated in 12 studies in which the patients received mitomycin C was of 69% (95% confidence interval [95%CI]: 61-76%; I2 = 17.3%). A total of 52% of the patients (95%CI: 39-64%, 11 studies; I2 = 64.7%) were submitted to a single endoscopic procedure, and 48% (95%CI: 36-61%, 11 studies; I2 = 64.7%) were submitted to more than 1 procedure. Complications (mediastinal and subcutaneous emphysema, dysphonia, laceration or vocal fold paralysis and acute light obstruction) were reported in 9% of the patients (95%CI: 3-18%, 9 studies; I2 = 79.8%). Conclusions The evidence suggests that mitomycin C is an effective and safe option in the endoscopic treatment of laryngotracheal stenosis.


Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Aged , Tracheal Stenosis/therapy , Laryngostenosis/therapy , Mitomycin/therapeutic use , Laryngoscopy/methods , Administration, Topical , Treatment Outcome , Mitomycin/administration & dosage , Combined Modality Therapy
9.
Rev. bras. oftalmol ; 78(4): 274-277, July-Aug. 2019. tab, graf
Article in Portuguese | LILACS | ID: biblio-1042376

ABSTRACT

Resumo A matriz de colágeno Ologen TM é um novo agente antifibrótico composto por uma matriz porosa de atelocolageno tipo I e glicosaminoglicanos reticulados, que pode ser utilizado como uma alternativa para a modulação da cicatrização nas cirurgias. Por ser altamente poroso e biodegradável, este implante auxilia nos processos de reparação fisiológicos que ocorrem no tecido conjuntivo e epitelial da lesão, sem a formação de tecido fibrótico, o qual acarreta insucesso cirúrgico e elevação da PIO. A Trabeculectomia (TREC) é considerada a cirurgia padrão para o tratamento do glaucoma, no entanto as taxas de sucesso cirúrgico a médio e longo prazo estão relacionadas a cicatrização do sítio operatório, envolvendo principalmente o tecido conjuntival e tenoniano. O processo de cicatrização é divido em 4 fases principais: coagulativa, inflamatória, proliferativa e remodeladora, com uma série de cascatas químicas e fatores bioquímicos liberados na tentativa de restabelecer a hemostasia. Diversas pesquisas na literatura já demonstraram os efeitos benéficos na cicatrização ao utilizar a matriz de colágeno Ologen em cirurgias oftalmológicas, além das possíveis complicações. Os resultados dos atuais estudos com implante de Ologen para o tratamento de glaucoma são encorajadores e promissores. No entanto, ensaios clínicos randomizados futuros com seguimento a longo prazo são necessários para avaliarmos a segurança e a eficácia do novo implante na modulação da cicatrização, alcançando melhores taxas de sucesso cirúrgico.


Abstract The Ologen™ collagen matrix is a new antifibrotic agent composed of a porous matrix of type I atelocolagene and cross-linked glycosaminoglycans, which can be used as an alternative for the modulation of healing in surgeries. Because it is highly porous and biodegradable, this implant assists in the physiological repair processes that occur in the connective and epithelial tissue of the lesion without the formation of fibrotic tissue, which leads to surgical failure and IOP elevation. The Trabeculectomy (TREC) is considered the standard surgery for the treatment of glaucoma; however, the surgical success rates in the medium and long term are related to surgical site healing, mainly involving conjunctival and tenonian tissue. The healing process is divided into 4 main phases: coagulative, inflammatory, proliferative and remodeling, with a series of chemical cascades and biochemical factors released in an attempt to restore hemostasis. Since several researches in the literature have already demonstrated the beneficial effects on healing by using the Ologen collagen matrix in ophthalmic surgeries, in addition to possible complications. The results of current Ologen implant studies for the treatment of glaucoma are encouraging and promising. However, future randomized clinical trials with long-term follow-up are necessary to evaluate the safety and efficacy of the new implant in modulating healing, achieving better rates of surgical success.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Wound Healing , Trabeculectomy/methods , Mitomycin/therapeutic use , Absorbable Implants , Comparative Study , Glaucoma/surgery , Retrospective Studies
10.
Rev. cuba. oftalmol ; 32(2): e717, abr.-jun. 2019. tab
Article in Spanish | LILACS | ID: biblio-1093685

ABSTRACT

RESUMEN Objetivo: Evaluar los resultados relacionados con la efectividad y la seguridad en el tratamiento con queratectomía subepitelial asistida por láser con mitomicina C versus queratectomía fotorreactiva con mitomicina C en ojos con miopía o astigmatismo miópico compuesto. Métodos: Se realizó un estudio experimental, longitudinal y prospectivo en el Instituto Cubano de Oftalmología Ramón Pando Ferrer entre abril del año 2016 y abril de 2017. Se empleó un muestreo aleatorio simple por el cual se obtuvo la técnica quirúrgica a realizar. El primer ojo operado fue el derecho y a la semana se realizó la cirugía en el ojo izquierdo, en el cual se aplicó la otra técnica quirúrgica. Esto permitió realizar en cada paciente ambas técnicas quirúrgicas. La muestra quedó constituida por 146 ojos (73 pacientes) que cumplían con los criterios de selección. Resultados: El comportamiento preoperatorio entre los dos grupos fue muy similar. En ninguno de los casos existieron diferencias en las variables que se evaluaron (agudeza visual sin corrección, agudeza visual mejor corregida, esfera, cilindro y equivalente esférico). La diferencia entre los valores preoperatorios y los encontrados a los 6 meses del tratamiento quirúrgico en cada grupo fueron estadísticamente significativos (p= 0,000) para todas las variables analizadas, excepto para la agudeza visual mejor corregida en el grupo de ojos tratados con láser con mitomicina C (p= 0,083). El haze y el defecto de epitelización fueron los dos tipos de complicaciones observadas. Conclusiones: Se demostró que ambas técnicas quirúrgicas son efectivas y seguras(AU)


ABSTRACT Objective: Evaluate the effectiveness and safety of laser-assisted subepithelial keratectomy with mitomycin C vs. photoreactive keratectomy with mitomycin C in eyes with myopia or compound myopic astigmatism. Methods: An experimental prospective longitudinal study was conducted at Ramón Pando Ferrer Cuban Institute of Ophthalmology from April 2016 to April 2017. Simple random sampling was used to decide on the surgical technique to be applied. Surgery was first performed on the right eye using one of the techniques, and then one week later on the left eye with the other technique. That way each patient could undergo both surgical techniques. The sample was composed of 146 eyes (73 patients) meeting the inclusion criteria. Results: Preoperative behavior was very similar in the two groups. In neither case were differences found in the variables analyzed (uncorrected visual acuity, best corrected visual acuity, sphere, cylinder and spherical equivalent). The differences between preoperative values and those found six months after surgery in each group were statistically significant for all the variables analyzed (p= 0.000), except for best corrected visual acuity in the group of eyes treated with laser with mitomycin C (p= 0.083). Haze and epithelization defect were the two types of complications observed. Conclusions: It was demonstrated that both surgical techniques are effective and safe(AU)


Subject(s)
Humans , Female , Adult , Mitomycin/therapeutic use , Photorefractive Keratectomy/methods , Keratectomy, Subepithelial, Laser-Assisted/methods , Lasers, Excimer/therapeutic use , Myopia/surgery , Prospective Studies , Longitudinal Studies
11.
Int. braz. j. urol ; 43(5): 939-945, Sept.-Oct. 2017. tab, graf
Article in English | LILACS | ID: biblio-892905

ABSTRACT

ABSTRACT Urethral stricture is a common disease with high recurrence rate. Several manipulations were defined to prevent the recurrence but the results were disappointing. This study aimed to evaluate the efficacy of triamcinolone and mitomycin-C on urethral stricture formation and their effect on inhibition of urethral fibrosis. A total of 24 New Zealand rabbits were divided into 3 groups. Urethras of rabbits were traumatized with pediatric resectoscope. Resection area was irrigated with 10mL saline, swapped with a cotton wool soaked with 0.5mg/mL MMC and injected by 40mg triamcinolone in groups 1, 2 and 3 respectively. Retrograde urethrogram was performed at 28th day of procedure and the urethra was removed for histopathologic evaluation. There were significant differences in urethral diameters and in lumen reduction rate between the control and study groups (p<0.001). Compared to control group, all treatment groups showed mild fibrosis, less collagen bundle irregularity, and lower numbers of fibroblasts (p=0.003). The Tunnel assay showed that the number of apoptotic cells in the submucosal connective tissue was quantitatively higher in control groups (p=0.034). In the view of efficacy and safety, MMC and triamcinolone have the potential to replace the use of stents, clean intermittent catheterization, or long term catheters following internal urethrotomy. There were no statistically significant differences between two agents in terms of preventing urethral stricture formation in the present study. Mitomycin C and triamcinolone decreased the recurrence rates of urethral stricture.


Subject(s)
Animals , Male , Urethral Stricture/prevention & control , Triamcinolone/therapeutic use , Mitomycin/therapeutic use , Rabbits , Disease Models, Animal
12.
Arq. bras. oftalmol ; 80(2): 131-136, Mar.-Apr. 2017. tab, graf
Article in English | LILACS | ID: biblio-838789

ABSTRACT

ABSTRACT In this systematic review, we evaluated studies involving adjuvant and primary topical treatment for ocular surface squamous neoplasia (OSSN). The findings were: (i) adjuvant 5-fluorouracil (5-FU) reduces the risk of relapse after surgical excision with mild side effects [level Ib, grade of recommendation (GR) A]. (ii) Primary topical mitomycin (MMC) produces a high rate of complete response, low recurrence rate, and mild side effects (level Ib, GR A). (iii) Primary chemotherapy versus adjuvant chemotherapy produce similar rates of recurrence, with no significant difference (level IIb, GR B). (iv) Adjuvant 5-FU versus MMC showed no significant differences, with mild side effects in both groups and a better toxicity profile for MMC (level III, GR C). (v) Primary topical 5-FU versus MMC versus interferon (IFN) showed similar rates of tumor recurrence, mild side effects for all drugs, and more severe side effects in the 5-FU arm, followed successively by MMC and IFN (level III, GR C).


RESUMO Revisão sistemática envolvendo estudos sobre o tratamento adjuvante e tratamento tópico primário para a neoplasia escamosa da superfície ocular. Os resultados foram: (i) 5-fluorouracil adjuvante reduziu o risco de recidiva após a excisão cirúrgica com efeitos colaterais leves (nível Ib, Grau de recomendação (GR) A). (ii) Mitomicina tópica primária produziu uma alta taxa de resposta completa, baixa taxa de recorrência e efeitos colaterais leves (nível Ib, GR A). (iii) Quimioterapia primária versus adjuvante produz taxas semelhantes de recorrência (nível IIb, GR B). (iv) 5- 5-FU versus mitomicina adjuvante não mostrou diferenças significativas nas taxas de recorrencia, com efeitos coalterais leves em ambos os grupos e melhor perfil de toxicidade para mitomicina (nível III, GR C). (v) 5- 5-FU tópico primário versus mitomicina ou interferon (INF) apresentam taxa similar de recorrência, com efeito colateral leve, mas com maior incidencia no braço 5- 5-FU, seguido pela Mitomicina e IFN (nível III, GR C).


Subject(s)
Humans , Carcinoma, Squamous Cell/drug therapy , Mitomycin/therapeutic use , Corneal Diseases/drug therapy , Eye Neoplasms/drug therapy , Fluorouracil/therapeutic use , Recurrence , Recombinant Proteins/therapeutic use , Administration, Topical , Chemotherapy, Adjuvant/methods , Conjunctival Neoplasms/drug therapy , Conjunctival Neoplasms/therapy , Corneal Diseases/therapy , Eye Neoplasms/therapy , Interferon alpha-2 , Antineoplastic Agents/therapeutic use
13.
Arq. bras. oftalmol ; 80(1): 25-29, Jan.-Feb. 2017. tab, graf
Article in English | LILACS | ID: biblio-838778

ABSTRACT

ABSTRACT Purpose: The aim of this study was to introduce a reproducible algorithm for the surgical management of late-onset (>2 months) bleb complications after trabeculectomy with mitomycin C. Methods: We performed a retrospective review of eyes treated using a reproducible algorithm approach by a single surgeon for the surgical management of late-onset bleb complications from July 2006 to April 2014. Exclusion criteria were bleb revision with less than 3 months of follow-up or bleb revision combined with other glaucoma procedures at the time of surgery. Success was evaluated using the Kaplan-Meier survival method and defined as achieving all of the following criteria: primary surgery indication resolved, no additional surgery required for decreasing the intraocular pressure (IOP), and IOP of ≥6 mmHg and ≤18 mmHg. Results: Twenty-three eyes from 20 patients were evaluated. Indications for bleb revision were hypotonic maculopathy (47.8%), bleb leak (30.4%), and dysesthetic bleb (21.7%). The overall primary outcome success rate calculated using the Kaplan-Meier survival method was 65.2% at 48 months. When the IOP target was changed to ≤15 mmHg, the bleb survival rate was 47.8% at 48 months. At the most recent postoperative visit, 95.7% of eyes had an IOP of ≤15 mmHg and 56.5% were being treated with an average of one medication per eye. One eye (4.3%) required a second bleb revision for persistent hypotony and two eyes required glaucoma surgery to reduce IOP during follow-up. Conclusions: An algorithm approach for the surgical management of late-onset bleb complications with a success rate similar to those reported in specialized literature is proposed. Randomized trials are needed to confirm the best surgical approach.


RESUMO Objetivo: Descrever um algoritmo reprodutível para o tratamento cirúrgico das complicações da bolha de início tardio (>2 meses) após trabeculectomia com mitomicina-C. Métodos: Revisão retrospectiva de olhos que foram submetidos a um algoritmo reprodutível para o tratamento cirúrgico das complicações da bolha de início tardio por um único cirurgião, de julho de 2006 a abril de 2014. Os critérios de exclusão foram revisão de bolha com menos de 3 meses de seguimento ou revisão de bolha combinado com outro procedimento antiglaucomatoso no momento da cirurgia. O sucesso foi avaliado pelo método de sobrevida de Kaplan-Meier e definidos como ter atingido todos os seguintes critérios: indicação de cirurgia primária resolvido, nenhuma cirurgia adicional necessária para diminuir a pressão intraocular (IOP), IOP ≥6 mmHg e ≤18 mmHg. Resultados: Vinte e três olhos de 20 pacientes foram incluídos. Indicações para revisão bolha foram maculopatia hipotônica (47,8%), extravasamento da bolha (30,4%) e bolha elevada (21,7%). A taxa de sucesso do resultado primário global calculada pelo método de sobrevivência de Kaplan-Meier foi de 65,2% aos 48 meses. Quando a IOP foi diminuída para ≤15mmHg, a taxa de sobrevivência bolha foi de 47,8% em 48 meses. Na visita pós-operatória mais recente, 95,7% dos olhos apresentavam PIO ≤15mmHg e 56,5% estavam sob tratamento com uma média de um medicamento por olho. Um olho (4,3%) necessitou de uma segunda revisão da bolha para hipotonia persistente e dois olhos necessitaram cirurgia de antiglaucomatosa para reduzir a IOP durante o seguimento. Conclusões: Um algoritmo de abordagem para o tratamento cirúrgico das complicações tardias da bolha com uma taxa de sucesso semelhante aos relatados na literatura especializada é proposto. Ensaios clínicos randomizados são necessários para confirmar a melhor abordagem cirúrgica.


Subject(s)
Humans , Male , Female , Middle Aged , Postoperative Complications/surgery , Reoperation , Algorithms , Trabeculectomy/adverse effects , Glaucoma/surgery , Blister/surgery , Postoperative Complications/drug therapy , Ocular Hypotension/surgery , Ocular Hypotension/etiology , Retrospective Studies , Follow-Up Studies , Blister/etiology , Mitomycin/therapeutic use , Cross-Linking Reagents/therapeutic use , Kaplan-Meier Estimate , Intraocular Pressure
14.
Rev. bras. oftalmol ; 75(5): 391-395, sept.-out. 2016. tab
Article in Portuguese | LILACS | ID: lil-798072

ABSTRACT

RESUMO Objetivo: Avaliar a segurança e eficácia de três técnicas distintas para o tratamento de neoplasia intraepitelial córneo-conjuntival. Métodos: Vinte e seis pacientes, 11 mulheres e 15 homens, com idade entre 32 e 88 anos (média 64,84 anos), atendidos entre 1999 e 2014, foram incluídos neste estudo. Todos os pacientes foram submetidos à exérese da lesão com margem de segurança de 4mm e crioterapia a 2mm do limbo. Conforme o tratamento complementar, os pacientes foram divididos em três grupos: Grupo 1 (8 olhos): recobrimento conjuntival e 2 ciclos de mitomicina C 0,02% (MMC) 4x/dia por 10 dias, com intervalo de 30 dias entre os ciclos. Grupo 2 (9 olhos): recobrimento com membrana amniótica e 3 ciclos de MMC 3x/dia por 10 dias, com intervalo de 10 dias entre o 1º e o 2º ciclo e 30 dias entre 2º e o 3º ciclo. Grupo 3 (9 olhos): recobrimento com membrana amniótica sem o uso de MMC. O acompanhamento dos pacientes variou de 3 meses a 14 anos (média: 4 anos). Resultados: Vinte e três pacientes apresentaram erradicação da lesão com um único tratamento. Três pacientes do Grupo 3 apresentaram recidiva da lesão após 3 meses, 6 meses e 1 ano do tratamento. Dois deles foram retratados pela técnica 1, sem nova recidiva após seguimento de 3 e 4 anos; o outro paciente foi submetido à enucleação. Não foram observados efeitos colaterais relacionados ao uso da mitomicina C durante o seguimento. Conclusão: Após exérese da lesão e crioterapia, os pacientes tratados com recobrimento conjuntival ou membrana amniótica associado à mitomicina C mostraram tendência a resultados mais eficazes.


ABSTRACT Purpose: To evaluate the safety and efficacy of three different techniques for the treatment of conjunctival-corneal intraepithelial neoplasia. Methods: Twenty-six eyes of 26 patients, 11 women and 15 men were included in a nonrandomized, retrospective, observational case series. Mean patient age was 64 years (range, 32-88 years).All patients were treated from 1999 to 2014. Mean postoperative follow-up was 4 years (range, 3 months to 14 years). All patients underwent excision of the lesion with a 4-mm safety margin and a 2-mm from the limbus cryotherapy. As further treatment the patients were divided into three groups: Group 1 (8 eyes): conjunctival autograft and 2 cycles of mitomycin C 0.02% (MMC) eye drops, four times daily for 10 days with an interval of 30 days between cycles. Group 2 (9 eyes): amniotic membrane (AM) graft and 3 cycles of MMC eye drops, three times daily for 10 days with an interval of 10 days between the 1st and 2nd cycle and 30 days between the 2nd and 3rd cycle. Group 3 (9 eyes): AM graft without MMC eye drops. Results: After a single treatment, the lesions were eradicated in twenty-three patients. Recurrence was noted in three patients from Group 3 at 3 months, 6 months and 1 year after treatment. Two of them were retreated by the technique used in Group 1 without further recurrence; the other patient underwent enucleation. No adverse effects related to the use of mitomycin C were observed during. There were no side effects related to the use of mitomycin C during follow-up. Conclusion: After surgical excision and cryotherapy, patients treated with conjunctival or amniotic membrane graft associated with mitomycin C, showed a tendency to more effective results.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Carcinoma in Situ/therapy , Mitomycin/therapeutic use , Cryotherapy , Conjunctival Neoplasms/therapy , Corneal Diseases/therapy , Amnion/transplantation , Ophthalmologic Surgical Procedures/methods , Carcinoma in Situ/surgery , Carcinoma in Situ/pathology , Carcinoma in Situ/drug therapy , Prospective Studies , Follow-Up Studies , Treatment Outcome , Limbus Corneae , Combined Modality Therapy , Conjunctival Neoplasms/surgery , Conjunctival Neoplasms/pathology , Conjunctival Neoplasms/drug therapy , Corneal Diseases/surgery , Corneal Diseases/pathology , Corneal Diseases/drug therapy , Neoplasm Recurrence, Local
15.
Rev. cuba. oftalmol ; 29(2): 189-198, abr.-jun. 2016. tab
Article in Spanish | LILACS | ID: lil-791536

ABSTRACT

Objetivo: determinar la efectividad a mediano plazo de la revisión con aguja asociada a mitomicina C en la ampolla de filtración encapsulada postrabeculectomía. Métodos: estudio observacional descriptivo, prospectivo de serie de casos (30 ojos, 30 pacientes), con antecedentes de quiste de Tenon a corto plazo postrabeculectomía (1 mes-1 año). Se realizó revisión con aguja asociada a inyección subconjuntival MMC 0,01 % hasta completar 3 dosis en días alternos. Se evaluaron la presión intraocular y el uso de colirios hipotensores preoperatorio y posoperatorio a la semana, 1 mes, 3 meses, 1 año y 2 años. Se definió éxito si la presión intraocular era menor de 21 mmHg sin colirio hipotensor (éxito total) y con colirios hipotensores (éxito parcial). Se registraron las complicaciones quirúrgicas. Resultados: hubo descenso significativo de la presión intraocular media preoperatoria de 27,06 ± 5,2 mmHg a 13,10 ± 3,65 mmHg, 14,83 ± 3,68 mmHg y 16,70 ± 3,38 mmHg a la semana, 1 y 3 meses posoperatorios respectivamente, y se mantuvo estable hasta 2 años (16,70 ± 2,18 mmHg); p< 0,001 para cada comparación preoperatorio vs. posoperatorio), lo que representó una reducción de la presión intraocular del 51,8 por ciento a la semana; 44,4 por ciento al mes y 37 por ciento hasta los 2 años. La media del número de colirios hipotensores se redujo significativamente de 2,0 ± 0,0 (preoperatorio) a 0,4 ± 0,0 (2 años posoperatorios), p< 0,001. El éxito fue total en el 70 por ciento de los casos y parcial en el 30 por ciento, tras 2 años posoperatorios. Las complicaciones fueron: hemorragia subconjuntival (100 por ciento de casos), atalamia (40 por ciento) y Seidel positivo (26,7 por ciento). Conclusiones: la revisión con aguja asociada a mitomicina C subconjuntival como tratamiento de la ampolla encapsulada, logra reducción del 37 por ciento de la presión intraocular durante los dos primeros años posoperatorios con un mínimo de complicaciones(AU)


Objective: to determine the medium-term effectiveness of subconjuntival mitomicyn-C associated to needle revision on encapsulated filtering bleb after trabeculectomy. Methods: prospective, descriptive and observational case series study (30 eyes, 30 patients) with a history of Tenon cyst after short term trabeculectomy (1month-1year). These patients underwent needle revision associated to subconjuntival 0,01 percent mitomycin injection to completing three doses in every other day. The intraocular pressure and the use of hypotensive drops preoperatively and postoperatively were evaluated seven days, one month, three months, one year and two years after the procedure. The success of intervention was defined as total when the intraocular pressure was less than 21mmHg without hypotensive drops and partial with hypotensive drops. Surgical complications were recorded. Results: the mean preoperative intraocular pressure decreased significantly from 27,06 ± 5,2 mmHg to 13,10 ± 3,3 mmHg, 14,83 ± 3,68 mmHg and 16,70 ± 3,38 mmHg one week, one month and three months after surgery and remained stable (16,70 ± 2,18 mmHg) for 2 years, p< 0,001 for each preoperative and postoperative comparison; this represented an intraocular pressure reduction of 51,8 percent; 44,4 percent and 37 percent after one week, one month, and up to 2 years, respectively. The mean number of hypotensive drops lowered significantly from 2,0 ± 0,0 (preoperative) to 0,4 ± 0,0 (two years after surgery), being p< 0,001. Total success was attained in 70 percent of cases and partial in 30 percent after 2 years. Surgical complications were subconjuntival haemorrhage (in all patients), atalamy (40 percent) and positive Seidel index (26,7 percent). Conclusion: subconjuntival mitomicyn-C injection-associated needle revision for encapsulated bleb reduces intraocular pressure by 37 percent during the first 2 years after the procedure with minimal complications(AU)


Subject(s)
Humans , Male , Female , Adult , Blister/therapy , Injections, Subcutaneous/statistics & numerical data , Mitomycin/therapeutic use , Trabeculectomy/adverse effects , Epidemiology, Descriptive , Observational Study , Ophthalmic Solutions/therapeutic use , Prospective Studies
16.
Arq. bras. oftalmol ; 79(2): 69-72, Mar.-Apr. 2016. tab, graf
Article in English | LILACS | ID: lil-782806

ABSTRACT

ABSTRACT Purpose: To evaluate the visual outcomes, recurrence patterns, safety, and efficacy of excimer laser phototherapeutic keratectomy (PTK) in conjunction with mitomycin C (MMC) for corneal macular and granular diystrophies. Methods: The patients were divided into two groups. Group 1 included patients with macular corneal dystrophy (MCD) that caused superficial corneal plaque opacities, and Group 2 included patients with granular corneal dystrophy (GCD). Patients in both groups were pre-, peri-, and postoperatively evaluated. The groups were compared in terms of uncorrected visual acuity (VA), best spectacle-corrected VA, presence of mild or significant recurrence, and time of recurrence. Results: Eighteen eyes (nine with MCD and nine with GCD) of 18 patients (10 men and eight women) were included. PTK was performed for each eye that was included in this study. The mean ablation amount was 117.8 ± 24.4 µm and 83.5 ± 45.7 µm in MCD and GCD, respectively, (p=0.18). The postoperative improvement of the mean VA was similar between the two groups before recurrences (p>0.43) and after recurrences (p>0.71). There were no statistically significant differences in the recurrence rate and the recurrence-free period for any recurrence type. Conclusion: PTK was an effective, safe, and minimally invasive procedure for patients with MCD and GCD. PTK in conjunction with MMC was similarly effective for both groups in terms of recurrence and visual outcomes.


RESUMO Objetivo: Avaliar os resultados visuais, padrões de recorrência, segurança e eficácia da ceratectomia fototerapêutica (PTK) por excimer laser em conjunto com mitomicina C (MMC) em distrofias macular e granular da córnea. Métodos: Os pacientes foram divididos em dois grupos. Grupo 1 incluiu pacientes com distrofia macular de córnea (MCD) que causaram opacidades superficiais corneanas em placa e o grupo 2 incluiu pacientes com distrofia corneana granular (GCD). Todos os pacientes em ambos os grupos foram avaliados no pré, per e pós-operatório. Os grupos foram comparados em termos de acuidade visual (VA) não corrigida, VA melhor corrigida por óculos, presença de recorrência leve ou significativa e o tempo de recorrência. Resultados: Dezoito olhos de 18 pacientes (10 homens e 8 mulheres) foram incluídos no estudo, 9 olhos com MCD e 9 olhos com GCD. Um procedimento de PTK foi realizado em cada olho incluídos neste estudo. A quantidade média de ablação foi 117,8 ± 24,4, 83,5 ± 45,7 µm de MCD e GCD, respectivamente, (p=0,18). A melhora pós-operatória da acuidade visual média foi semelhante entre os dois grupos antes de as recidivas (p>0,43) e após as recidivas (p>0,71). Não houve diferença estatisticamente significativa na taxa de recorrência ou do período livre de recorrência para qualquer tipo de recorrência. Conclusão: PTK foi um procedimento eficaz, seguro e minimamente invasivo para pacientes MCD e GCD. PTK em conjunto com MMC é igualmente eficaz para ambos os grupos em termos de recorrência e resultados visuais.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Young Adult , Corneal Dystrophies, Hereditary/therapy , Mitomycin/therapeutic use , Photorefractive Keratectomy/methods , Alkylating Agents/therapeutic use , Lasers, Excimer/therapeutic use , Postoperative Complications , Recurrence , Time Factors , Visual Acuity , Retrospective Studies , Follow-Up Studies , Treatment Outcome , Mitomycin/administration & dosage , Photorefractive Keratectomy/adverse effects , Corneal Opacity/therapy , Lasers, Excimer/adverse effects
17.
Int. braz. j. urol ; 42(1): 22-28, Jan.-Feb. 2016. tab, graf
Article in English | LILACS | ID: lil-777329

ABSTRACT

ABSTRACT Objectives To evaluate the clinical practice of non-muscle invasive bladder cancer (NMIBC) treatment in Brazil in relation to international guidelines: Sociedade Brasileira de Urologia (SBU), European Association of Urology (EAU) and American Urological Association (AUA). Materials and Methods Cross-sectional study using questionnaires about urological practice on treatment of NMIBC during the 32nd Brazilian Congress of Urology. A total of 650 question forms were answered. Results There were 73% of complete answers (total of 476 question forms). In total, 246 urologists (51.68%) lived in the southeast region and 310 (65.13%) treat 1 to 3 cases of NMIBC per month. Low risk cancer: Only 35 urologists (7.5%) apply the single intravesical dose of immediate chemotherapy with Mitomicin C recommended by the above guidelines. Adjuvant therapy with BCG 2 to 4 weeks after TUR is used by 167 participants (35.1%) and 271 urologists (56.9%) use only TUR. High risk tumors: 397 urologists (83.4%) use adjuvant therapy, 375 (78.8%) use BCG 2 to 4 weeks after TUR, of which 306 (64.3%) referred the use for at least one year. Intravesical chemotherapy with Mitomicin C (a controversial recommendation) was used by 22 urologists (4.6%). BCG dose raised a lot of discrepancies. Induction doses of 40, 80 and 120mg were referred by 105 (22%), 193 (40.4%) and 54 (11.3%) respectively. Maintenance doses of 40, 80 and 120mg were referred by 190 (48.7%), 144 (37.0%) and 32 (8.2%) urologists, respectively. Schemes of administration were also varied and the one cited by SWOG protocol was the most used: 142 (29.8%). Conclusion SBU, EAU and AUA guidelines are partially respected by Brazilian urologists, particularly in low risk tumors. In high risk tumors, concordance rates are comparable to international data. Further studies are necessary to fully understand the reasons of such disagreement.


Subject(s)
Humans , Urinary Bladder Neoplasms/therapy , Practice Patterns, Physicians'/statistics & numerical data , Practice Guidelines as Topic , Guideline Adherence , Time Factors , Urinary Bladder Neoplasms/pathology , Brazil , BCG Vaccine/therapeutic use , Cross-Sectional Studies , Surveys and Questionnaires , Treatment Outcome , Mitomycin/therapeutic use , Risk Assessment , Antineoplastic Agents, Alkylating/therapeutic use , Neoplasm Grading
18.
Arq. bras. oftalmol ; 78(6): 363-366, Nov.-Dec. 2015. tab, graf
Article in English | LILACS | ID: lil-768169

ABSTRACT

ABSTRACT Purpose: To quantitatively analyze corneal esthesia in patients undergoing photorefractive keratectomy (PRK) surgery. Methods: Forty-five patients selected for PRK in one eye underwent corneal esthesia using a Cochet-Bonnet esthesiometer preoperatively and 30 and 90 days postoperatively. Patients with a refractive diopter error of 4 or greater received intraoperative 0.02% mitomycin C for 20 s. Results: Twenty-four (53.3%) of the 45 eyes received intraoperative 0.02% mitomycin. Decreased sensitivity was observed on postoperative day 30. By postoperative day 90, corneal esthesia had normalized but remained 14.9% lower than preoperative levels. In the mitomycin group, no recovery of corneal esthesia to normal sensitivity levels was observed. The mean esthesiometer level was 39.2 mm on postoperative day 90 (P<0.001). Conclusions: The results of the present study demonstrate recovery of corneal esthesia to normal levels at 90 days postoperatively in patients who did not receive mitomycin C. In patients administered mitomycin C, a 23.59% reduction in the corneal touch threshold was observed compared with preoperative levels indicating a failure of recovery to normal levels.


RESUMO Objetivo: Análise quantitativa da estesia corneal em pacientes submetidos à cirurgia refrativa (PRK). Métodos: Estudo prospectivo, longitudinal e intervencionista, analisando 45 olhos com estesiômetro de Cochet Bonnet no período pré-operatório, no 30º dia após a cirurgia e no 90º dia após cirurgia refrativa. Os pacientes com erro refracional maior ou igual a 4 dioptrias, foram submetidos ao uso de mitomicina 0,02%, por período de 20 segundos no intraoperatório. Resultados: Observou-se diminuição da sensibilidade corneal no 30º dia em todos os olhos, retornando a níveis próximo ao normal no 90º dia, apresentando redução média final de 14,9%. Mitomicina C foi utilizada em 24 (53,3%) dos 45 olhos examinados. No grupo que recebeu mitomicina C, não houve recuperação da estesia normal (média de 39,2 mm) (p<0,001), após 90 dias de cirurgia. Conclusão: Com base nos resultados obtidos, verificamos que ocorreu recuperação da estesia corneal próximo ao normal 90 dias após a cirurgia, porém inferior aos valores iniciais, no grupo sem o uso de mitomicina C intraoperatória. No entanto, no grupo submetido ao uso de mitomicina, não houve a recuperação da sensibilidade corneal a níveis normais, mesmo após o período de 90 dias.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Young Adult , Cornea/physiopathology , Cornea/surgery , Lasers, Excimer/therapeutic use , Photorefractive Keratectomy/methods , Intraoperative Period , Lasers, Excimer/adverse effects , Mitomycin/therapeutic use , Nucleic Acid Synthesis Inhibitors/therapeutic use , Postoperative Period , Prospective Studies , Photorefractive Keratectomy/adverse effects , Reference Values , Sensation Disorders/etiology , Time Factors , Treatment Outcome
19.
Acta cir. bras ; 30(9): 593-597, Sep. 2015. tab
Article in English | LILACS | ID: lil-761492

ABSTRACT

PURPOSE:To compare histologically the action of Mitomycin C and that of Clobetasol propionate for surgical wound healing in rats.METHODS:A circular skin fragment was surgically removed from 57 Wistar rats. Twenty-two animals were treated with Mitomycin C with topical medication in a single dose, 22 with Clobetasol propionate with a cream medication once a day for 15 days and 13 did not receive any medication. The animals were euthanized 30 and 60 days, and the scars subjected to histological examination.RESULTS: The histological analysis on the samples did not show statistically significant differences regarding the quantities of fibroblasts, fibrocytes and vascular proliferation in the three groups, in the evaluations after 30 and 60 days. In the treated groups with Mitomycin C and Clobetasol there was a decrease in collagen concentration over the 30-day period and an increase in collagen concentration over the 60-day period, in comparison with the control group.CONCLUSIONS: The actions of Mitomycin C and Clobetasol were equivalent and not interfere in fibroplasias and in angiogenesis. Both drugs initially cause a decrease in collagen over a 30-day period and an increase over a 60-day period, demonstrating a delay in the wound healing.


Subject(s)
Animals , Male , Alkylating Agents/therapeutic use , Clobetasol/therapeutic use , Glucocorticoids/therapeutic use , Mitomycin/therapeutic use , Wound Healing/drug effects , Administration, Topical , Cell Proliferation/drug effects , Collagen/analysis , Collagen/drug effects , Fibroblasts/drug effects , Rats, Wistar , Reproducibility of Results , Skin/drug effects , Skin/pathology , Time Factors , Treatment Outcome
20.
Arq. bras. oftalmol ; 78(4): 255-256, July-Aug. 2015. ilus
Article in English | LILACS | ID: lil-759263

ABSTRACT

ABSTRACTWe report a case of primary acquired corneal melanosis without atypia associated with corneal haze in a patient with a history of limbal malignant melanoma and the effect of mitomycin-C. A 75-year-old woman with a history of limbal malignant melanoma presented with loss of vision in right eye. Corneal examination showed a patchy melanotic pigmentation with a central haze. Topical mitomycin-C improved visual acuity and corneal haze. However, the pigmented lesions persisted, and they were removed with alcohol corneal epitheliectomy. Histopathological examination demonstrated primary acquired melanosis without atypia. The lesions were successfully removed, and there were no recurrences during the follow-up period of 36 months. The association of conjunctival and corneal melanosis without atypia is a rare condition. In addition, co-existence of central corneal haze and melanosis may decrease visual acuity. Topical mitomycin-C and alcohol corneal epitheliectomy can be useful treatments in this condition.


RESUMORelatar um caso de melanose adquirida primária de córnea sem atipia, associado a haze corneano em um paciente com história de melanoma maligno de limbo e o efeito da mitomicina-C. Uma mulher de 75 anos de idade, com história de melanoma maligno do limbo apresentado com diminuição de visão no olho direito. O exame de córnea mostrou uma pigmentação melânica irregular com um haze central. O uso de mitomicina-C tópica levou à melhora da acuidade visual e da opacidade corneana. No entanto, as lesões pigmentadas persistiram e foram removidas com epiteliectomia associada ao álcool. O exame histopatológico demonstrou melanose adquirida primária sem atipia. As lesões foram removidas com êxito, e não houve recidiva durante o período de acompanhamento de 36 meses. A associação melanose sem atipia da conjuntiva e da córnea é uma condição rara. Além disso, a coexistência de haze corneano central e melanose pode diminuir a acuidade visual. O uso de mitomicina-C tópica e epiteliectomia corneana auxiliada pelo álcool podem ser tratamentos úteis nessa situação.


Subject(s)
Aged , Female , Humans , Antibiotics, Antineoplastic/therapeutic use , Corneal Diseases/drug therapy , Melanosis/drug therapy , Mitomycin/therapeutic use , Combined Modality Therapy , Conjunctival Neoplasms/complications , Corneal Diseases/etiology , Follow-Up Studies , Melanoma/complications , Melanosis/etiology , Treatment Outcome , Visual Acuity
SELECTION OF CITATIONS
SEARCH DETAIL